Malvern, PA – According to filings with the U.S. Securities and Exchange Commission, Early Bird Medical is raising $12,535,417.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Skott Greenhalgh played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Early Bird Medical
Developer of a medical device designed to revolutionise the future of women’s health. The company’s device is a catheter-based technology that contains a unique fabric that grasps cells as it navigates through the fallopian tubes during a hysteroscopic procedure and collects cells that can be tested for early cancer indicators, enabling healthcare providers to detect the early stages of ovarian cancer, provide initial treatment and reduce unnecessary fertility ending surgeries. The Hummingbird Device is a catheter-based technology that contains a unique fabric that easily grasps cells as it navigates through the tortuous fallopian tubes. Used during a simple hysteroscopic procedure in the office, the Hummingbird device collects cells that can be tested for early cancer indicators. The presence or absence of these indicators will allow for earlier treatment and reduce unnecessary fertility ending surgeries.

To learn more about Early Bird Medical, visit http://www.earlybirdmed.com/

Contact:
Skott Greenhalgh, President and Chief Executive Officer
215-962-2733

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved